Astrazeneca PLC (NYSE:AZN) :The total money flow, which is calculated as the dollar value of composite uptick minus downtick trades was negative ($6 million) and the uptick to downtick ratio was 0.76. The transaction value on upticks was $18.59 million and on downticks, the transaction value was $24.59 million. The transaction value of block trades during downticks was $1.29 million. The money flow was negative ($1.29 million), indicating the traders were booking profit on the price strength. Astrazeneca PLC (NYSE:AZN) rose $0.75 at $29.84, during intraday Wednesday , a rise of 2.58% over the previous days close.
Institutional Investors own 10.17% of Astrazeneca PLC shares.
The company shares have dropped -9.99% from its 1 Year high price. On Dec 1, 2015, the shares registered one year high at $34.88 and the one year low was seen on Jun 16, 2016. The 50-Day Moving Average price is $28.80 and the 200 Day Moving Average price is recorded at $29.92. Astrazeneca PLC (NYSE:AZN): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $29.68 and $29.41 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $30.12. The buying momentum continued till the end and the stock did not give up its gains. It closed at $29.85, notching a gain of 2.61% for the day. The total traded volume was 6,757,438 . The stock had closed at $29.09 on the previous day.
AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. The Company discovers, develops and commercializes prescription medicines for cardiovascular and metabolic diseases; oncology; respiratory, inflammation and autoimmunity, and infection, neuroscience and gastrointestinal. Its medicines include Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension, heart failure and angina; Iressa for lung cancer; Faslodex for breast cancer; Zoladex for prostate and breast cancer; Nexium for acid-related diseases; Seroquel XR for schizophrenia, bipolar disorder and depressive disorder, and Synagis for RSV (respiratory syncytial virus), a respiratory infection in infants. It also offers potassium-binding compound sodium zirconium cyclosilicate (ZS-9), a treatment for hyperkalaemia, a condition associated with increased mortality in patients with chronic kidney disease (CKD), diabetes mellitus (DM) and chronic heart failure (CHF).